CohBar — Non-Deal Roadshow (April 2015)
54 slides from CohBar's roadshow presentation, Apr 8, 2015
Slide 1: Meeting with Investors, Vancouver, B.C.
1 COHBAR, INC. Meeting with Investors Vancouver, B.C. April 8, 2015
Slide 2: Legal Disclaimer
2 COHBAR, INC. This presentation includes forward - looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future plans, intentions, expectations, business prospects and opportunities.
Slide 3: Live Longer, Live Well (video clip)
3 COHBAR, INC. Live Longer, Live Well (video clip) American Federation for Aging Research (AFAR) www.afar.org
Slide 4: Agenda
4 COHBAR, INC. • Live Longer, Live Well - AFAR Video • Introductions - Albion Fitzgerald (Chairman) • How to die young at a very old age - Nir Barzilai (Founder ) • Break • CohBar Science - Ken Cundy (CSO) • CohBar Business - Jon Stern (CohBar CEO) Agenda
Slide 5: Pinchas Cohen, MD and Nir Barzilai, MD
5 COHBAR, INC. Pinchas Cohen, MD • Dean of the Davis School of Gerontology at the University of Southern California • Executive Director of the Ethel Percy Andrus Gerontology Center • William and Sylvia Kugel Dean’s Chair in Gerontology • Recipient of n umerous awards for research, including the Nat
Slide 6: Jon Stern and Kenneth Cundy
6 COHBAR, INC. Jon Stern, MBA Chief Executive Officer • Senior business executive with over 30 years of diversified management experience • COO of The Key Worldwide, EVP of Integrated China Media and VP of IMC, a division of Kaufman and Broad, CEO and Founder of Cine Coasters, Inc., acquired by divi
Slide 7: Board of Directors
7 COHBAR, INC. Albion Fitzgerald Chairman • Over 45 years of experience in the technology sector • Member of the board of directors since May 2014 and appointed chairman in July 2014 • Previously CEO and Chairman of ManageIQ , Inc., Co - Founder, CEO and Chairman of Novadigm , Inc. (NASDAQ: NVDM) an
Slide 8: How to Die Young at a Very Old Age
8 COHBAR, INC. How to Die Young at a Very Old Age CohBar Founder Nir Barzilai M.D. Professor of Medicine and Genetics Director: Institute for Aging Research PI: Glenn Center for the Biology of Human Aging The Nathan Shock Center of Excellence in the Biology of Aging Albert Einstein College of Medici
Slide 9: Aging is the major risk factor for death from chronic diseases
9 COHBAR, INC. Kidney disease 10000 1000 100 10 1 0 100000 Deaths per 100,000 per year Heart disease Cancer Stroke Emphysema Pneumonia Diabetes Accidents Alzheimer’s Aging is the major risk factor for death from all chronic diseases Source: NIH
Slide 10: What is the evidence for success in delaying aging?
10 COHBAR, INC. AGING CELLS AGING GENOME AGING METABOLISM Longevity • Healthy life - span has been extended by genetic ( GH/IGF - 1 ), environmental and drug interventions in numerous models • Relevant drugs have been used in humans ( Metformin , Acarbose , Rapalogs , etc.) • Aging is not an FDA ind
Slide 11: Do humans age at different rates?
11 COHBAR, INC. Do humans age at different rates?
Slide 12: Lifespan vs. Healthspan
12 COHBAR, INC. Graph ©Mark Collins - Glenn Foundation Lifespan vs. Healthspan
Slide 13: Exceptional and Healthy Longevity
13 COHBAR, INC. Exceptional and Healthy Longevity
Slide 14: Irving Kahn (video clip)
14 COHBAR, INC. http:// www.einstein.yu.edu /centers/aging/longevity - genes - project/ Irving Kahn (video clip)
Slide 15: Centenarians end-of-life medical costs are significantly lower
15 COHBAR, INC. 0 5,000 10,000 15,000 20,000 25,000 60-70 Yo >100 Yo 24,000 8,000 Centers for Disease Control: Most Recently Available Data Centenarians end - of - life medical costs are Significantly lower
Slide 16: Centenarians: Interaction with the environment
16 COHBAR, INC. • Overweight /obese: 48 % 44 % • Smoking: 60 % 30 % • Alcohol (daily): 24 % 12 % • Physical activity , 43 % 47% (walking, bicycling, housework) • Vegetarians: 2.6 % Centenarians Men Women Swapnil Rajpathak , Jill Crandall, J Am Geriatr Soc. 2011 Aug 3 ‘ Environmental ’ risk Centenari
Slide 17: Jay Leno – Tonight Show (video clip)
17 COHBAR, INC. Jay Leno – Tonight Show (Video Clip) http:// www.nbc.com /the - tonight - show/classic/jay - leno/episodes
Slide 18: Offspring are less likely to have age-related diseases
18 COHBAR, INC. 0 5 10 15 20 25 30 35 40 Diabetes Mellitus (%) Miocardial Infarction (%) Stroke (%) Prevalence in population Hypertension (% ) JAGS 2004; 52:274 P O C ** ** ** ** Centenarians Offspring (~70 yrs old) Control (~70 yrs old) ** p<0.01 Offspring are less likely to have age - related dise
Slide 19: Diminished GH/IGF-1 and longevity
19 COHBAR, INC. Ghr - / - , lit/lit , GHA, Wt , bGH Ponies live longer than thoroughbreds Small dogs live longer than large dogs Longer lifespan in daf - 2 mutants Longevity Genotyping IGF1R Mutations 700 subjects revealed 9 centenarians vs. 1 control (~2%) harbor nonsynonymous mutations (p<0.02) an
Slide 20: From the DNA of the Nucleus to the DNA of the mitochondria
20 COHBAR, INC. mitochondria nucleus Cell Membrane CohBar : From the DNA of the Nucleus to the DNA of the mitochondria Genome of mitochondria and mitochondrial - derived peptides (MDPs): A N ew U ntapped Field in Biology
Slide 21: Mitochondria: Overview
21 COHBAR, INC. Originally a bacteria, helped survive oxidative environment and provides for energy (ATP)! Mitochondrial function declines with age Mitochondrial dysfunction is common in many diseases (i.e. diabetes and neurodegeneration ) Mitochondria are key to cell energy, metabolism & life - cyc
Slide 22: Humanin: The First Mitochondrial Peptide
22 COHBAR, INC. 24 amino acid peptide transcribed from within the mitochondrial DNA • Produced from the mitochondria • Expressed and secreted • Present in tissues • Detected in spinal fluid, and Plasma • P rotects against cell death and Alzheimer’s • R egulator of glucose metabolism Humanin : The Fi
Slide 23: Frieda's birthday: Humanin levels
23 COHBAR, INC. Frieda’s 100 birthday: Humanin levels over 2000!
Slide 24: Humanin as an indicator of healthy aging
24 COHBAR, INC. Humanin declines with aging but is higher in offspring of centenarians when compared to an age and gender matched control group Humanin is lower in humans with poor endothelial function, a major risk factor cardiovascular diseases Humanin as an indicator of healthy aging Offspring wi
Slide 25: Questions?
25 COHBAR, INC. Questions?
Slide 26: CohBar Science
26 COHBAR, INC. CohBar Science Ken Cundy (Chief Scientific Officer)
Slide 27: Mitochondrial Biology and Genomics
27 COHBAR, INC. Mitochondria are components within the cell that produce energy and regulate cell death in response to signals received from the cell. Mitochondrial Genomics: • Mitochondria are the only cell components besides the nucleus that have their own DNA. • Until recently, scientists believe
Slide 28: MDPs – A New Untapped Field of Biology
28 COHBAR, INC. MDP Biological Effects: • Influence cellular activities by acting as messengers between cells, triggering intra - cellular changes • M etabolic effects, neuro - protective effects, cyto - protective effects and anti - inflammatory effects • Humanin , the first MDP discovered in 2001
Slide 29: CohBar Founders' MDP Discoveries
29 COHBAR, INC. MDP’s have the potential to lead to novel mitochondria - based therapeutics (MBTs) for a number of diseases with significant unmet medical needs. 1. MOTS - c • P lays a significant role in regulation of metabolism • Potential source of MBTs to treat T ype 2 Diabetes, obesity, and fat
Slide 30: MDP Optimization and Development into MBTs
30 COHBAR, INC. CohBar MBT Optimization Process: • Synthesis of analogs of native MDP • Physicochemical Properties • Solubility • Chemical stability • Resistance to Enzymatic Degradation • Stability in tissues • Efficacy • In vitro cell - based assays • In vivo disease models • Pharmacokinetics • Ha
Slide 31: CohBar MDP: MOTS-c
31 COHBAR, INC. MOTS - c Glucose Regulation Fatty Acids Amino Acids Cell Death DNA Synthesis Mitochondrial Metabolism CohBar MDP: MOTS - c A Key Regulator of Metabolism
Slide 32: CohBar MDP: MOTS-c
32 COHBAR, INC. Soleus Muscle 2 - DG Uptake (3 mo. Vs 12 mo. Mice) MOTS - c reverses age - dependent insulin resistance in mice MOTS - c prevents weight gain in mice on a high fat diet The Company plans to advance research on MOTS - c and novel MBT analogs of MOTS - c as our lead program, which we b
Slide 33: CohBar MDP: SHLP-6
33 COHBAR, INC. 0 0.2 0.4 0.6 0.8 1.0 1.2 Control staining intensity (CD31) P = 0.004 0 1 2 3 4 5 6 7 Control SHLP - 6 staining intensity (TUNEL) P = 0.03 Increased Cancer Cell Death Reduced Tumor Blood Vessel Development SHLP - 6 * P< 0.01 Injection day * * * * * SHLP - 6 Control Scrambled Peptide
Slide 34: CohBar MDPs – Diseases and Patents
34 COHBAR, INC. Granted / Filed Composition Claims Type 1 Diabetes Type 2 Diabetes Obesity Fatty Liver Cancer Alzheimer’s Atherosclerosis MOTS - c Filed x x x x x x SHLP - 6 Filed x x SHLP - 2 Granted x x x x Humanin Analogs Granted x x Humanin Analogs Two Granted x Humanin & Humanin Analogs Filed x
Slide 35: Target diseases of drug discovery efforts
35 COHBAR, INC. The Company’s drug discovery efforts are centered on the identification of MDPs that have potential for further development as MBT drug candidates for these major diseases: Type 2 Diabetes and Obesity – The World Health Organization (“WHO”) reports that over 346 million people worldw
Slide 36: Type 2 Diabetes Worldwide Market
36 COHBAR, INC. Source: Evaluate Pharma, 2015 • $ 60 billion market by 2020 • Some drugs sell ̴$billions/year Type 2 Diabetes Worldwide Market (MOTS - c and Humanin Analogs)
Slide 37: Obesity Worldwide Market
37 COHBAR, INC. Source: Evaluate Pharma, 2015 • Rapidly growing market projected to more than triple to ca. $4B by 2020 Obesity Worldwide Market (MOTS - c)
Slide 38: Cancer Worldwide Markets
38 COHBAR, INC. Prostate Cancer Breast Cancer Source: Evaluate Pharma, 2015 • >$12 billion by 2020 • >$25 billion by 2020 Cancer Worldwide Markets (MOTS - c and SHLPs)
Slide 39: Alzheimer's Disease Worldwide Market
39 COHBAR, INC. Source: Evaluate Pharma, 2015 • Growing market; lack of treatments • >$ 7 billion by 2020 Alzheimer’s Disease Worldwide Market (SHLPs)
Slide 40: Cardiovascular Disease Worldwide Market
40 COHBAR, INC. Source: Evaluate Pharma, 2015 • Large market >$40 billion • Growth affected by generics Cardiovascular Disease Worldwide Market ( Humanin Analogs)
Slide 41: CohBar Objectives
41 COHBAR, INC. Selection of an MBT drug candidate: • Evaluation of existing MDPs and any newly discovered MDPs • Determination of initial activity in efficacy models • Prioritization of potential lead molecules • Synthesis of new analogs (MBTs) • Iterative evaluation of stability , pharmacokinetics
Slide 42: CohBar Business
42 COHBAR, INC. CohBar Business Jon Stern (Chief Executive Officer)
Slide 43: CohBar 2014 – Statement of Operations
43 COHBAR, INC. CohBar 2014 – Statement of Operations
Slide 44: CohBar Balance Sheet, 12/31/2014
44 COHBAR, INC. CohBar Balance Sheet, 12/31/2014
Slide 45: CohBar – 2014 Accomplishments
45 COHBAR, INC. CohBar – 2014 Accomplishments • Research and Development: CohBar Lab, CRO’s, Academia • Management T eam : Search and hire of Ken Cundy (CSO) • Corporate Governance: Expanded Board, Albion Fitzgerald and Marc Goldberg Engaged auditors, Marcum LLP (May) • Financing(s): Series B Prefer
Slide 46: CohBar Operating Plan, 2015
46 COHBAR, INC. I ncreasing investment in R&D • New Laboratory and capital equipment • Adding Scientific Staff: Hiring experienced scientists and lab technicians • Establishing relationships with domain specific leading scientific consultants • Expanding our academic research collaborations • Increa
Slide 47: CohBar 1st Quarter 2015 Update
47 COHBAR, INC. • Completed $11.25M IPO and concurrent $2.70M private placement • Established new CohBar Lab in Menlo Park, California • Initiated work under CohBar - USC Sponsored Research Agreement • E ngaged MacDougall Biomedical Communications for Corporate S trategy and Investor Relations • Fea
Slide 48: MOTS-c paper featured in Cell Metabolism
48 COHBAR, INC. Major Findings for MOTS - c: • Originates in mitochondria • Regulates insulin sensitivity and metabolic homeostasis • Counteracts insulin resistance - a critical feature of type - 2 diabetes • Prevents obesity in mice on a high fat diet Article response : • Time (online), BioCentury
Slide 49: New CohBar Menlo Park Lab
49 COHBAR, INC. • I deal facility for early - stage companies • Located close to Stanford and Silicon Valley biotech companies • Initial 1500 square feet with space for expansion as needed • Fully outfitting with equipment • Pasadena lab relocated New CohBar Menlo Park Lab
Slide 50: Strategy: build a multi-product MBT company
50 COHBAR, INC. To b uild a multi - product company based on our expertise in MDP biology that, discovers , develops and commercializes first - and best - in - class mitochondria - based therapeutics (MBTs) for diseases with large unmet medical needs: • Maintain our first mover advantage in MDP disc
Slide 51: Projected Development Timeline and Milestones
51 COHBAR, INC. Projected Development Timeline and Milestones
Slide 52: Upcoming Shareholder Events
52 COHBAR, INC. • Annual shareholder meeting on June 9, 2015 – virtual • 2 nd Quarter Investor call, TBA Upcoming Shareholder Events
Slide 53: Questions?
53 COHBAR, INC. Questions?
Slide 54: Meeting with Investors, Vancouver, B.C.
54 COHBAR, INC. Meeting with Investors Vancouver, B.C. April 8, 2015